查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1586252

化疗贫血市场：按贫血范围、治疗方法、药物和最终用户 - 2025-2030 年全球预测

Chemotherapy Induced Anemia Market by Range Of Anemia (Life-Threatening Anemia, Mild Anemia, Moderate Anemia), Treatment (Erythropoiesis-Stimulating Agents, Iron Supplementation, RBC Transfusions), Drug, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年化疗引起的贫血市值为25.1亿美元，预计2024年将达到27亿美元，复合年增长率为7.36%，预计到2030年将达到41.4亿美元。

化疗引起的贫血（CIA）是癌症治疗的严重併发症，被定义为由于化疗导致红血球减少而导致体内携带的氧气量减少。解决 CIA 问题的必要性在于它对患者生活品质的影响，表现为疲劳和身体功能下降，从而阻碍了癌症治疗方法的有效性。在CIA管理的应用主要集中在造血刺激因子製剂、铁补充剂、红血球输注等。最终用途范围主要是医院和癌症治疗中心，这突显出需要有效的策略来减轻贫血的影响。 CIA 管理市场受到多种因素的影响，包括癌症发生率上升、化疗的进步以及对支持性护理需求的认识。新型疗法和生技药品的进步也推动了市场成长，提供了透过创新解决方案和与研究机构合作获取价值的潜在机会。例如，人们对生物相似药和个人化医疗方法的开发越来越感兴趣。然而，治疗高成本、潜在副作用和监管挑战等限制因素可能会阻碍市场扩张。此外，COVID-19 大流行导致肿瘤护理的运作中断，可能会暂时影响成长轨迹。有创新机会来提高目前 CIA 干预措施的有效性并减少副作用，包括开发现有药物的靶向输送系统以及可纳入综合护理计划的营养和替代疗法的研究。製药和生物技术部门之间的合作至关重要。此外，利用资料分析来更深入了解患者人口统计和治疗结果可能会产生新的见解，并实现适合个人需求的方法。总体而言，CIA 市场复杂且充满活力，需要采取包括市场分析在内的平衡方法来克服挑战并抓住新机会。

主要市场统计
基准年[2023] 25.1亿美元
预测年份 [2024] 27亿美元
预测年份 [2030] 41.4亿美元
复合年增长率（%） 7.36%

市场动态：快速发展的化疗贫血市场的关键市场洞察

供需的动态交互作用正在改变化疗贫血市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 老年人癌症和贫血盛行率增加
    • 化疗药物数量的增加
    • 政府积极研发药物治疗化疗引起的贫血
  • 市场限制因素
    • 化疗期间与贫血相关的某些风险
  • 市场机会
    • 化疗引起的贫血领域的创新
    • 加大协作研究与投入，加强贫血药物研发
  • 市场挑战
    • 化疗引起的血小板减少性疾病减少症治疗效果降低

波特的五力：驾驭化疗贫血市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解化疗贫血市场的外部影响

外部宏观环境因素在塑造化疗引起的贫血市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助企业预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解化疗贫血市场的竞争状况

对化疗贫血市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵化疗贫血市场供应商绩效评估

FPNV定位矩阵是评估化疗引起的贫血市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

透过策略分析和化疗建议规划您在贫血市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对化疗贫血市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 老年患者癌症和贫血的发生率增加
      • 化疗药物的可用性增加
      • 政府优先致力于开发治疗化疗引起的贫血的药物
    • 抑制因素
      • 化疗期间与贫血相关的特定风险
    • 机会
      • 化疗引起的贫血领域的创新
      • 加大合作与投入，加强贫血药物研发研发
    • 任务
      • 化疗引起的血小板减少性疾病减少症治疗效果降低
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 贫血市场化疗引起的贫血范围

  • 危及生命的贫血
  • 轻度贫血
  • 中度贫血
  • 严重贫血

第七章 贫血化疗治疗市场

  • 促红细胞生成素
  • 补铁
  • 红血球输注

第八章化疗药物的贫血市场

  • 雄性激素口服液
  • 花生注射液
  • 阿尔法依泊汀注射液
  • epogen注射液
  • Procrit注射

第 9 章化疗引起的贫血市场：按最终用户

  • 门诊手术中心
  • 癌症復健中心
  • 癌症研究中心
  • 医院
  • 多学科诊所

第10章美洲化疗引起的贫血市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区化疗贫血市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲化疗引起的贫血市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • 3SBIO Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • Dr. Reddy's Laboratories Ltd.
  • F. Hoffmann-La Roche Ltd.
  • FibroGen, Inc.
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Pfizer Inc.
  • PhytoHealth Corporation
  • SBI Pharmaceuticals
  • Therapure Biopharma Inc.
Product Code: MRR-CA17E905E925

The Chemotherapy Induced Anemia Market was valued at USD 2.51 billion in 2023, expected to reach USD 2.70 billion in 2024, and is projected to grow at a CAGR of 7.36%, to USD 4.14 billion by 2030.

Chemotherapy induced anemia (CIA) represents a significant complication in cancer treatment, defined as a decrease in red blood cells due to chemotherapy, leading to reduced oxygen transportation in the body. The necessity of addressing CIA is underscored by its impact on patient quality of life, manifesting as fatigue and decreased physical function, which can hinder the efficacy of cancer treatment regimens. Applications of CIA management primarily focus on hematopoiesis-stimulating agents, iron supplements, or red blood cell transfusions. End-use scope predominantly involves hospitals and cancer treatment centers, emphasizing the need for effective strategies to mitigate anemia's impacts. The market for CIA management is influenced by several factors, including the rising prevalence of cancer, advancements in chemotherapy, and awareness about supportive care needs. The progression of novel therapies and biologics also stimulates market growth, offering potential opportunities to capture value through innovative solutions and partnerships with research institutions. For instance, there is growing interest in the development of biosimilars and personalized medicine approaches. However, limitations such as the high cost of therapeutics, potential side effects, and regulatory challenges could dampen market expansion. Additionally, the COVID-19 pandemic has brought operational disruptions in oncology care that might temporarily affect growth trajectories. Opportunities for innovation lie in improving efficacy and reducing the side effects of current CIA interventions, such as developing targeted delivery systems for existing drugs, or exploring nutritional and alternative therapies that can be integrated into comprehensive care plans. Collaborative initiatives across the pharmaceutical and biotech sectors will be crucial. Moreover, utilizing data analytics to better understand patient demographics and treatment outcomes could foster new insights, tailoring approaches to individual needs. Overall, the CIA market is complex and dynamic, necessitating a balanced approach that includes market analysis to navigate its challenges and capture emerging opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 2.51 billion
Estimated Year [2024] USD 2.70 billion
Forecast Year [2030] USD 4.14 billion
CAGR (%) 7.36%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Chemotherapy Induced Anemia Market

The Chemotherapy Induced Anemia Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cancer and anemia among geriatric patients
    • Rising availability of number of chemotherapy agents
    • Favorable governmental initiatives in development of chemotherapy-induced anemia drugs
  • Market Restraints
    • Certain risks associated with anemia during chemotherapy
  • Market Opportunities
    • Innovations in the field of chemotherapy-induced anemia
    • Increasing collaborations and investments to enhance the research and development for anemia drug developments
  • Market Challenges
    • Lower efficacy of the chemotherapy-induced thrombocytopenia treating drugs

Porter's Five Forces: A Strategic Tool for Navigating the Chemotherapy Induced Anemia Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Chemotherapy Induced Anemia Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Chemotherapy Induced Anemia Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Chemotherapy Induced Anemia Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Chemotherapy Induced Anemia Market

A detailed market share analysis in the Chemotherapy Induced Anemia Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Chemotherapy Induced Anemia Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Chemotherapy Induced Anemia Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Chemotherapy Induced Anemia Market

A strategic analysis of the Chemotherapy Induced Anemia Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chemotherapy Induced Anemia Market, highlighting leading vendors and their innovative profiles. These include 3SBIO Inc., Amgen Inc., Astellas Pharma Inc., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., FibroGen, Inc., Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., PhytoHealth Corporation, SBI Pharmaceuticals, and Therapure Biopharma Inc..

Market Segmentation & Coverage

This research report categorizes the Chemotherapy Induced Anemia Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Range Of Anemia, market is studied across Life-Threatening Anemia, Mild Anemia, Moderate Anemia, and Severe Anemia.
  • Based on Treatment, market is studied across Erythropoiesis-Stimulating Agents, Iron Supplementation, and RBC Transfusions.
  • Based on Drug, market is studied across Androxy Oral, Aranesp Injection, Epoetin Alfa Injection, Epogen Injection, and Procrit Injection.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Cancer Rehabilitation Centers, Cancer Research Centers, Hospitals, and Multispecialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer and anemia among geriatric patients
      • 5.1.1.2. Rising availability of number of chemotherapy agents
      • 5.1.1.3. Favorable governmental initiatives in development of chemotherapy-induced anemia drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Certain risks associated with anemia during chemotherapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations in the field of chemotherapy-induced anemia
      • 5.1.3.2. Increasing collaborations and investments to enhance the research and development for anemia drug developments
    • 5.1.4. Challenges
      • 5.1.4.1. Lower efficacy of the chemotherapy-induced thrombocytopenia treating drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Chemotherapy Induced Anemia Market, by Range Of Anemia

  • 6.1. Introduction
  • 6.2. Life-Threatening Anemia
  • 6.3. Mild Anemia
  • 6.4. Moderate Anemia
  • 6.5. Severe Anemia

7. Chemotherapy Induced Anemia Market, by Treatment

  • 7.1. Introduction
  • 7.2. Erythropoiesis-Stimulating Agents
  • 7.3. Iron Supplementation
  • 7.4. RBC Transfusions

8. Chemotherapy Induced Anemia Market, by Drug

  • 8.1. Introduction
  • 8.2. Androxy Oral
  • 8.3. Aranesp Injection
  • 8.4. Epoetin Alfa Injection
  • 8.5. Epogen Injection
  • 8.6. Procrit Injection

9. Chemotherapy Induced Anemia Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Cancer Rehabilitation Centers
  • 9.4. Cancer Research Centers
  • 9.5. Hospitals
  • 9.6. Multispecialty Clinics

10. Americas Chemotherapy Induced Anemia Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Chemotherapy Induced Anemia Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Chemotherapy Induced Anemia Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 3SBIO Inc.
  • 2. Amgen Inc.
  • 3. Astellas Pharma Inc.
  • 4. Dr. Reddy's Laboratories Ltd.
  • 5. F. Hoffmann-La Roche Ltd.
  • 6. FibroGen, Inc.
  • 7. Johnson & Johnson Services, Inc.
  • 8. Novartis AG
  • 9. Pfizer Inc.
  • 10. PhytoHealth Corporation
  • 11. SBI Pharmaceuticals
  • 12. Therapure Biopharma Inc.

LIST OF FIGURES

  • FIGURE 1. CHEMOTHERAPY INDUCED ANEMIA MARKET RESEARCH PROCESS
  • FIGURE 2. CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CHEMOTHERAPY INDUCED ANEMIA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CHEMOTHERAPY INDUCED ANEMIA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHEMOTHERAPY INDUCED ANEMIA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CHEMOTHERAPY INDUCED ANEMIA MARKET DYNAMICS
  • TABLE 7. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY LIFE-THREATENING ANEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY MILD ANEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY MODERATE ANEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY SEVERE ANEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY ERYTHROPOIESIS-STIMULATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY IRON SUPPLEMENTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RBC TRANSFUSIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY ANDROXY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY ARANESP INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY EPOETIN ALFA INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY EPOGEN INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY PROCRIT INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY CANCER REHABILITATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY MULTISPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY RANGE OF ANEMIA, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM CHEMOTHERAPY INDUCED ANEMIA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. CHEMOTHERAPY INDUCED ANEMIA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 197. CHEMOTHERAPY INDUCED ANEMIA MARKET, FPNV POSITIONING MATRIX, 2023